Intel is changing its AI strategy. The company is now focusing on building complete AI systems and infrastructure, not just chips. This mov...

Artificial intelligence is increasingly being used to process complex genetic data, enabling new approaches in biological research. This sh...

The Bengaluru-based firm said the new vehicle will invest between $500,000 and $3 million in IP-led firms across these sectors. The launch ...

In a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

IIT Roorkee has launched the Ashok Soota Molecular Medicine Facility, a state-of-the-art platform for advanced biomedical research, drug di...

India's leading veterinary vaccine manufacturers, including Hester Biosciences and Indian Immunologicals, have formed the Veterinary Vaccin...

Anthem Biosciences IPO allotment date: The allotment for Anthem Biosciences IPO is now complete. Investors can check their status on KFin T...

IIT Kanpur, in partnership with the Wadhwani Foundation, is launching the Wadhwani School of Advanced Artificial Intelligence and Intellige...

For venture capital firms like Aeravti Ventures and Capital-A, DeepTech is not just a promising investment category—it represents the futur...

Anthem Biosciences has selected JM Financial as the lead banker for its IPO, along with Citi and JP Morgan. The company plans to raise Rs 3...

For merger of Diavetra, GAFL and Hester Mauritius into Hester India, no shares of Hester India will be issued on amalgamation, Hester Biosc...

The Hyderabad-based firm and Onconova have entered into a JV to develop new drugs for cancer, GVK Biosciences said in a statement.

A BTA has been entered between Hester and Innoves. Hester acquired the products, the brands and the marketing network of Innoves

Hyderabad-based Jupiter Biosciences is in talks to buy privately held Swiss pharma company SynphaBase AG for about $10 million as it looks ...

As blockbuster drugs are set to lose exclusivity in the US, Indian pharma companies are gearing up to tap the fast-growing generic peptide ...

Ranbaxy Laboratories is about to enter into a 10-year co-marketing agreement with Jupiter Bioscience to tap the $6-billion global peptide p...